2023-505299-31-00已完成1 期
A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Abivax
- 入组人数
- 32
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Operations
Scientific
Abivax
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.2024-514561-20-00Abivax48
招募中
1 期
Phase 1 study to investigate the pharmacokinetic profile and safety of 3 testosterone gel formulations in postmenopausal female participants.2025-522726-12-00Chemo Research S.L.24
招募中
4 期
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected MelanomaMelanoma2025-522307-14-00Intas Pharmaceuticals Limited19
招募中
1 期
Phase I Study of CPD704 Inhalation Suspension in Healthy SubjectsNCT07301203Beijing Tide Pharmaceutical Co., Ltd90
招募中
1 期
A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy SubjectsNCT07300189OrsoBio, Inc332